title: [Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].
abstract: Prevalence and therapy of infections due to MRSA remain one of the most serious problems in the world. Therefore, correct laboratory identification of the MRSA phenotype based on the use of the marker antibiotic cefoxitine, as a more susceptibile one vs. oxacillin, is of great importance. There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin and daptomycin. Susceptibility of MSRA to these drugs was not investigated in Russia and there are no data on the prevalence of the VISA and hVISA phenotypes. The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein. It was shown that the ranges of the oxacillin MIC were extremely wide, i. e. 0.5 to 512 mcg/ml, while 2.2 +/- 1% of the isolates was susceptible by the phenotype to oxacillin, in spite of the mecA gene presence. As for cefoxitine, the MRSA isolates were rather resistant to it at the MIC > 16 mcg/ml. The tests with serial microdilutions revealed that 30.7 +/- 7% of the isolates had a critical level of susceptibility to vancomycin at the MIC 2 mcg/ml. The E-tests revealed 1.3 +/- 1% of the isolates which were susceptible at the MIC 2-4 mcg/ml. The MRSA isolates were highly susceptible to daptomycin, while high levels of the MIC (2 mcg/ml) were characteristic of 2.8 +/- 1% of the isolates. Cross reduction of the susceptibility to vancomycin and daptomycin was observed.
authors.forename: V V
authors.initials: VV
authors.lastname: Gostev
authors.forename: L N
authors.initials: LN
authors.lastname: Popenko
authors.forename: T V
authors.initials: TV
authors.lastname: Chernen'kaia
authors.forename: Z S
authors.initials: ZS
authors.lastname: Naumenko
authors.forename: T M
authors.initials: TM
authors.lastname: Voroshilova
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Zakharova
authors.forename: O E
authors.initials: OE
authors.lastname: Khokhlova
authors.forename: A N
authors.initials: AN
authors.lastname: Kruglov
authors.forename: M G
authors.initials: MG
authors.lastname: Ershova
authors.forename: S N
authors.initials: SN
authors.lastname: Angelova
authors.forename: E D
authors.initials: ED
authors.lastname: Poletaeva
authors.forename: I V
authors.initials: IV
authors.lastname: Molchanova
authors.forename: S V
authors.initials: SV
authors.lastname: Sidorenko
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002440:Cefoxitin / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000166:cytology / Q000254:growth & development / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D002440:Cefoxitin; D014640:Vancomycin; D017576:Daptomycin; D010068:Oxacillin